What the Component Research Studies Used — and Why No KLOW Dosing Protocol Exists

The short version

KLOW peptide is supplied as a research vial — most often 80 mg total: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg. This page documents what doses were used in the component research studies and explains why no validated human dosing protocol exists for the blend.

The short answer: no controlled study has ever tested the four together. Each component was studied alone in cells and animals, at doses specific to the species and route used. Those rodent doses cannot be converted into a human protocol — not because the math is hard, but because the pharmacokinetics and pharmacodynamics of the blend in humans are completely uncharacterized.

There is also an inherent pharmacokinetic mismatch inside the vial: the two tripeptides (KPV and GHK-Cu) clear faster than BPC-157, and the TB-500 fragment has different kinetics from native thymosin beta-4. A single co-formulated dose produces a temporal cascade of exposures, not four simultaneous peaks. This has never been measured or optimized.

What follows is a research-context summary, not a dosing guide. 'In rodent studies, doses of X were used by Y route' is the language here — never 'take X mg per day.'

KLOW peptide dosage: the 80 mg vial composition

The canonical KLOW research vial as listed across independent compounders carries 80 mg total in a lyophilized (freeze-dried) format, reconstituted with bacteriostatic water for laboratory handling. The composition: GHK-Cu 50 mg (approximately 62.5% of the total by mass), BPC-157 10 mg, TB-500 10 mg, KPV 10 mg.

This is a co-formulation — four separate compounds dissolved together at fixed mass ratios. No FDA pharmacopeial standard exists for this mixture. The mass ratios represent the most common independent-compounder specification, not a clinically validated formula.

Copper from GHK-Cu: the 50 mg of GHK-Cu delivers a meaningful copper load. GHK-Cu is a 1:1 chelate of the Gly-His-Lys tripeptide with copper(II); the molecular weight is 402.92 Da (including the copper). This is a theoretical consideration for copper-handling disorders.

KLOW dosage in the component research literature

TB-500 arm (thymosin beta-4 studies): In the rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization 42% at four days and 61% at seven days; as little as 10 picograms stimulated keratinocyte migration 2-3-fold in culture ^[1]. In rodent angiogenesis/wound/hair studies, doses were at nanomolar concentrations in vitro and study-specific amounts in vivo ^[9]. These are doses of full-length thymosin beta-4 (43 amino acids), not the TB-500 heptapeptide fragment.

BPC-157 arm: In rat Achilles tendon transection studies, doses of 10 micrograms, 10 nanograms or 10 picograms per rat were administered intraperitoneally once daily ^[2] — a remarkably wide effective dose range (covering nine orders of magnitude) with consistent effects across it. In the 2025 first-in-human IV safety pilot: 10 mg on day one and 20 mg on day two in 250 mL saline as a one-hour infusion in two adults ^[6].

GHK-Cu arm: In vitro effects on fibroblast gene expression at 1-10 nM in cell culture ^[4][5]. In the human hair study (ALAVAX topical): 50 mg/mL and 100 mg/mL formulations applied to the scalp for six months ^[8]. In topical skin-regeneration clinical data: formulation-specific concentrations in placebo-controlled studies ^[4]. In the murine scald-wound model: liposomal GHK-Cu topical ^[10].

KPV arm: In mice (DSS/TNBS colitis): 100 micromolar in drinking water ^[3]. In cell culture: 10 nM for in vitro NF-kappaB and MAPK effects ^[3]. Substrate Km for the PepT1 transporter: approximately 160 micromolar — the concentration at which transport rate is half-maximal.

These are research doses in species-specific studies. They do not translate directly into a human protocol for the co-formulated blend.

KLOW peptide dosage and frequency: what does not exist

No validated human dosing protocol exists for the KLOW blend. No pharmacokinetic study has characterized the blend in humans. No dose-ranging or dose-finding trial has been run for any constituent in this context. The answer to 'How much KLOW peptide per day?' is: no human study has established this — and given the pharmacokinetic mismatch among the four components, the question may not have a single answer.

The pharmacokinetic mismatch in detail: BPC-157 has been reported with a short elimination half-life in rodent plasma (on the order of tens of minutes in formal pharmacokinetics work); KPV and GHK-Cu as tripeptides are expected to clear faster; the TB-500 heptapeptide fragment's half-life differs from the 43-amino-acid native protein's. In a single co-formulated vial, these four components reach peak concentrations and clear at different rates — producing a temporal cascade of exposures rather than a synchronized multi-arm hit.

Routes studied in the component literature include subcutaneous and intraperitoneal injection (research handling), topical application (GHK-Cu), oral/targeted delivery (KPV, BPC-157), and intra-articular injection (BPC-157). The blend has not been characterized by any of these routes in a formal study.

The canonical research vial is lyophilized (freeze-dried powder). Copper(II) in GHK-Cu can participate in redox chemistry; co-dissolving it with three other peptides in one vial raises a theoretical compatibility and oxidation question that has not been formally characterized for this mixture.

KLOW dosage context: what this site does and does not report

This site documents what doses were administered in which studies to which species. It does not translate rodent doses into human recommendations. It does not reproduce community-reported protocols, because those protocols are unverified and involve an unapproved research blend. It does not recommend any dose, frequency or route.

For the component research context in depth, see the KLOW research and KLOW results pages. For the safety cautions relevant to any research-use context, see the KLOW effects page.